tbuckley/cabot-search huggingface dataset:
β内酰胺类抗生素与对非典型病原体有效的抗生素——在非重症社区获得性肺炎中的疗效比较：汇总分析
Authors: Graham, Mills, Michael, Oehley, Bruce, Arrol, 刘艳（译）, 代华平（校）
Journal: BMJ (2005)

目的对于社区获得性肺炎，将β内酰胺类抗生素与对非典型病原体有效的抗生素进行全面系统的疗效比较。资料来源Medline、Embase、Cochrane登记注册的对照试验、国际性会议的会议纪录、药品注册机构以及制药公司。评价方法通过总结双盲、随机、对照、单一给药疗法试验，对β内酰胺类抗生素与对非典型病原体有效的抗生素在成人社区获得性肺炎的疗效方面进行比较。主要结局指标是未达到临床治愈或好转。结果18项临床试验共纳入6749例受试者，其中大多数患者有轻至中度社区获得性肺炎。对各种原因引起的社区获得性肺炎治疗失败的相对危险度进行分析，结果显示对非典型病原体有效的抗生素并不优于β内酰胺类抗生素（0．97，95％可信区间：0．87—1．07）。对于有特异性非典型病原体感染诊断的患者进行亚组分析，我们发现应用对非典型病原体有效的抗生素治疗军团菌属感染的肺炎患者，其治疗无效率明显的低一些（0．40，0．19～0．85）。而在肺炎支原体（0．60，0．31～1．17）和肺炎衣原体（2．32，0．67～8．03）感染的肺炎患者中二者的疗效相似。结论应用对非典型病原体有效的抗生素治疗由各种原因引起的非重症社区获得性肺炎，而使临床疗效得到提高的证据是不足的。尽管此类抗生素在对稍后介绍的军团菌感染相关性肺炎的治疗方面显示出明显的优势，但已纳入研究范围内的肺炎病例很少是由这种病原体引起的。β内酰胺类制剂应该继续作为成人非重症社区获得性肺炎治疗的首选抗生素。
FEV<sub>1</sub>and MRI ventilation defect reversibility in asthma and COPD
Authors: Hana Serajeddini, Rachel L. Eddy, Christopher Licskai, David G. McCormack, Grace Parraga
Journal: European Respiratory Journal (2019)

<b>MRI ventilation defect post-bronchodilator reversibility was not always concordant with FEV<sub>1</sub> reversibility in asthma and COPD. MRI VDP may provide enhanced sensitivity to small airway response to inhaled medication.</b>http://bit.ly/2qKnwID
Development of a prediction model for inpatient gout flares in people with comorbid gout
Authors: Kanon Jatuworapruk, Rebecca Grainger, Nicola Dalbeth, William J. Taylor
Journal: Annals of the Rheumatic Diseases (2019)

Hospitalisation is a risk factor for flares in people with gout. However, the predictors of inpatient gout flare are not well understood. The aim of this study was to develop a prediction model for inpatient gout flare among people with comorbid gout.We used data from a retrospective cohort of hospitalised patients with comorbid gout from Wellington, Aotearoa/New Zealand, in 2017 calendar year. For the development of a prediction model, we took three approaches: (A) a clinical knowledge-driven model, (B) a statistics-driven model and (C) a decision tree model. The final model was chosen based on practicality and performance, then validated using bootstrap procedure.The cohort consisted of 625 hospitalised patients with comorbid gout, 87 of whom experienced inpatient gout flare. Model A yielded 9 predictors of inpatient gout flare, while model B and C produced 15 and 5, respectively. Model A was chosen for its simplicity and superior C-statistics (0.82) and calibration slope (0.93). The final nine-item set of predictors were pre-admission urate >0.36 mmol/L, tophus, no pre-admission urate-lowering therapy (ULT), no pre-admission gout prophylaxis, acute kidney injury, surgery, initiation or increase of gout prophylaxis, adjustment of ULT and diuretics prior to flare. Bootstrap validation of the final model showed adequate C-statistics and calibration slope (0.80 and 0.78, respectively).We propose a set of nine predictors of inpatient flare for people with comorbid gout. The predictors are simple, practical and are supported by existing clinical knowledge.
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
Authors: Zachary S Wallace, Ray P Naden, Suresh Chari, Hyon K Choi, Emanuel Della-Torre, Jean-Francois Dicaire, Phillip A Hart, Dai Inoue, Mitsuhiro Kawano, Arezou Khosroshahi, Marco Lanzillotta, Kazuichi Okazaki, Cory A Perugino, Amita Sharma, Takako Saeki, Nicolas Schleinitz, Naoki Takahashi, Hisanori Umehara, Yoh Zen, John H Stone
Journal: Annals of the Rheumatic Diseases (2019)

IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serological, radiological and pathological data is required for diagnosis. This work was undertaken to develop and validate an international set of classification criteria for IgG4-RD. An international multispecialty group of 86 physicians was assembled by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). Investigators used consensus exercises; existing literature; derivation and validation cohorts of 1879 subjects (1086 cases, 793 mimickers); and multicriterion decision analysis to identify, weight and test potential classification criteria. Two independent validation cohorts were included. A three-step classification process was developed. First, it must be demonstrated that a potential IgG4-RD case has involvement of at least one of 11 possible organs in a manner consistent with IgG4-RD. Second, exclusion criteria consisting of a total of 32 clinical, serological, radiological and pathological items must be applied; the presence of any of these criteria eliminates the patient from IgG4-RD classification. Third, eight weighted inclusion criteria domains, addressing clinical findings, serological results, radiological assessments and pathological interpretations, are applied. In the first validation cohort, a threshold of 20 points had a specificity of 99.2% (95% CI 97.2% to 99.8%) and a sensitivity of 85.5% (95% CI 81.9% to 88.5%). In the second, the specificity was 97.8% (95% CI 93.7% to 99.2%) and the sensitivity was 82.0% (95% CI 77.0% to 86.1%). The criteria were shown to have robust test characteristics over a wide range of thresholds. ACR/EULAR classification criteria for IgG4-RD have been developed and validated in a large cohort of patients. These criteria demonstrate excellent test performance and should contribute substantially to future clinical, epidemiological and basic science investigations.
Helen Salisbury: Measuring continuity of care
Authors: Helen Salisbury
Journal: BMJ (2019)

“My biggest problem is that thanks to NHS cuts it is impossible to see the same GP twice—unless I want to wait weeks—and it is so humiliating to explain my history to yet another relative stranger.” This sentiment was expressed by a patient on Twitter recently, and it’s likely that others share this feeling.

Continuity matters to patients, and it matters to doctors too. When discussing the appeal of a career in general practice with newly qualified doctors, continuity of care is a key factor. GPs see their patients for minor illnesses and major ones, …
Problems and Potentials of Automated Object Detection for Skin Cancer Recognition
Authors: Philipp Tschandl
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Intrusive thoughts in perinatal obsessive-compulsive disorder
Authors: Fiona L Challacombe, Maria Bavetta, Stephanie DeGiorgio
Journal: BMJ (2019)

### What you need to know A 25 year old woman with a four month old baby presents with severe anxiety. She is experiencing intrusive thoughts of deliberately harming her child. She is reluctant to disclose details of her symptoms. She tells you that she is currently avoiding time with the baby if possible and does not change his nappy alone for fear of harming him. Her partner is aware that she is struggling but does not understand what she is experiencing. Obsessive-compulsive disorder (OCD) affects 2-4% of women during pregnancy and postnatally, and is thought to be more common during this period.1 It can also affect fathers. Intrusive thoughts are a characteristic feature of OCD, and may lead to compulsive behaviour and high levels of anxiety (box 1). Intrusive thoughts in OCD are unwanted and distressing to the patient, and are particularly frightening if the thoughts become focused on a parent harming their baby. Assessing a woman who is pregnant or postnatal or their partner presenting with intrusive thoughts involves sensitive communication and a careful consideration of risks. This article describes the specific challenges in the assessment and management of intrusive thoughts and OCD in the perinatal period. Box 1 ### Intrusive thoughts "Intrusive thoughts" is the term for a range of mental phenomena including thoughts, images, doubts, and urges that are experienced as unwanted and distressing. The content of the thoughts typically relates to some form of threat. This threat may be external (for … RETURN TO TEXT
Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion
Authors: Yong Li, Xian Chen, Yanchun Qu, Jia-Ming Fan, Yan Li, Hui Peng, Yaojie Zheng, Yihong Zhang, Hai-Bo Zhang
Journal: Journal of the National Comprehensive Cancer Network (2019)

Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, there is no standard treatment for recurrence or unresectable tumors. Almost 50% of IMTs carry ALK gene rearrangement that can be treated using ALK inhibitors, but therapeutic options for ALK -negative tumors are limited. This report describes a woman aged 22 years with unresectable ALK -negative IMT. Next-generation sequencing revealed a TFG-ROS1 fusion, and she had a partial response to the ROS1 inhibitor ceritinib. This report provides the first published demonstration of a patient with IMT with ROS1 fusion successfully treated using ceritinib. Our study suggests that targeting ROS1 fusions using the small molecule inhibitor shows promise as an effective therapy in patients with IMT carrying this genetic alteration, but this requires further investigation in large clinical trials.
Identification of ADRA2A Polymorphisms Related to Shear-Mediated Platelet Function by the PFA-100® System.
Authors: Mariko Yabe, Yumiko Matsubara, Shinichi Takahashi, Hiroaki Ishihara, Toshiro Shibano, Koichi Miyaki, Kazuyuki Omae, Gentaro Watanabe, Mitsuru Murata, Yasuo Ikeda
Journal: Blood (2006)
Parent-Measured and Parent-Estimated Child’s Heights and Weights—Reply
Authors: Punam Ohri-Vachaspati, Francesco Acciai, Derek DeLia
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract 1883: Long Term Echocardiographic and Clinical Outcome in Congestive Heart Failure Patients With “Normalized” Left Ventricular Ejection Fraction After Beta-Blocker Therapy
Authors: Pascal De Groote, Nicolas Lamblin, Frederic Mouquet, Joel Dagorn, Olivier Hennebert, Eric Tison, Christine Verkindere, Thierry Le Tourneau, Christophe Bauters
Journal: Circulation (2006)

Background: Previous studies have demonstrated a significant improvement in left ventricular ejection fraction (LVEF) after beta-blocker therapy (BB) in patients (pts) with stable congestive heart ...
Inflammatory markers in early-stage breast cancer.
Authors: Hilbrahim Petekkaya, Sercan Aksoy, Gizem Gecmez, Emre Kulahcioglu, Alexis K. Okoh, Deniz Cagın Isler, Abdullah Fatih Demirci, Ugur Sahin, Erkan Dogan, Kadri Altundag
Journal: Journal of Clinical Oncology (2013)

e11537 Background: In a few number of studies a possible relationship between inflammatory markers and the prognosis, chemotherapy response and survival in breast cancer has been reported. The aim of this study is to point out the place of serum markers as a prognostic factor in early stage breast cancer. Methods: This study was conducted in Hacettepe University Cancer Institute. Patients operated and stage IA to III C for breast cancer between December 2009 and June 2012 were included the study. Before the any adjuvant therapy inflammation markers were studied. Results: A total of 704 patients were included in the study. The median age of the patients was 50 (25-92). 42,8% of the patients were premenopausal and 48,2% postmenopausal. The median follow up period for the whole study group was 22 months (3-287). We studied the CRP, erythrocyte sedimentation rate, B2 microglobulin, LDH, albumin, and ferritin studied and values for each marker were grouped as high and normal. There was no statistically significant difference in disease free survival and overall survival for each marker who had high and normal levels. Conclusions: We did not found any inflammatory markers as a prognostic value. However our follow up time is short and we should be wait for more mature data.
Silent synapses dictate cocaine memory destabilization and reconsolidation
Authors: William J. Wright, Nicholas M. Graziane, Peter A. Neumann, Peter J. Hamilton, Hannah M. Cates, Lauren Fuerst, Alexander Spenceley, Natalie MacKinnon-Booth, Kartik Iyer, Yanhua H. Huang, Yavin Shaham, Oliver M. Schlüter, Eric J. Nestler, Yan Dong
Journal: Nature Neuroscience (2019)
Reduced-Intensity Conditioning Regimen with BEAM/Rituximab for Patients with Refractory Non-Hodgkin’s Lymphomas.
Authors: Issa F. Khouri, Rima M. Saliba, Grace-Julia Okoroji, Sandra Acholonu, Farzaneh Maadani, Chitra Hosing, Richard E. Champlin
Journal: Blood (2004)
Diffuse pontine gliomas in children: Do changing strategies change results?
Authors: Rejin Kebudi, Betul Cakir, Fulya Yaman Agaoglu, Emin Darendeliler, Omer Gorgun, Nergis Dagoglu, Inci Ayan, Yavuz Dizdar, Bulent Zulfikar, Basak Koc
Journal: Journal of Clinical Oncology (2012)

9567 Background: The prognosis of children with diffuse intrinsic pontine gliomas (DIPG) is dismal. Despite various studies undertaken to improve outcome, radiotherapy (RT) remains the standard treatment, which is mostly palliative. This study aims to evaluate characteristics and treatment outcome of children with DIPG in a single center. Methods: We retrospectively reviewed the demographic, clinical characteristics and treatment outcome of children with DIPG treated at Istanbul University, Oncology Institute from 1999 to 2011. We also evaluated the group that prospectively recieved RT with concurrent and adjuvant temozolamide after 2004. Results: 47 children (24 female, 23 male) with the median age of 7 years (6 months-16 years) were analyzed. The median duration of symptoms was 30 days (2-630 days). The frequent clinical findings were ataxia, strabismus and motor weakness. All patients received RT, 54-60 Gy to the tumor site. 12 recieved only RT. 35 had concomitant and/or adjuvant chemotherapy with RT. 8 recieved cisplatinum, 7 vincristine. Since 2004, 20 patients recieved the institutional protocol consisting of temozolomide (TMZ) (75 mg/m2/day) for 6 weeks concurrent with RT, followed by TMZ (200 mg/m2/day) for 5 days every 28 days for 12 cycles or until progression. There was no major side effect due to TMZ, thrombocytopenia being the most frequent, but managable side effect. The median overall survival after diagnosis was 13 months (3-132 mo.) for the whole group. The median overall survival in 20 patients that received RT and TMZ [ 17 months (3-132 months)], was significantly superior than that in 12 patients that recieved only RT [ 12 months (3-20 months)] ( (p=0.03). Nimotuzumab was given to 4 patients that progressed after RT and TMZ. There was no major side effect due to nimotuzumab. One was stable for 1 year with significant clinical improvement, the others were stable for 5, 2 and 2 months after nimotuzumab. Conclusions: In our series, the median survival was significantly superior in patients who received RT with concurrent and adjuvant temozolamide in comparison to patients that recieved RT alone. Nimotuzumab may be promising in some progressive patients, its role as upfront treatment needs further investigation.
The transcription factor NFAT5 limits infection-induced type I interferon responses
Authors: Hector Huerga Encabo, Laia Traveset, Jordi Argilaguet, Ana Angulo, Estanislao Nistal-Villán, Rahul Jaiswal, Carlos R. Escalante, Christos Gekas, Andreas Meyerhans, Jose Aramburu, Cristina López-Rodríguez
Journal: The Journal of Experimental Medicine (2019)

Type I interferon (IFN-I) provides effective antiviral immunity but can exacerbate harmful inflammatory reactions and cause hematopoietic stem cell (HSC) exhaustion; therefore, IFN-I expression must be tightly controlled. While signaling mechanisms that limit IFN-I induction and function have been extensively studied, less is known about transcriptional repressors acting directly on IFN-I regulatory regions. We show that NFAT5, an activator of macrophage pro-inflammatory responses, represses Toll-like receptor 3 and virus-induced expression of IFN-I in macrophages and dendritic cells. Mice lacking NFAT5 exhibit increased IFN-I production and better control of viral burden upon LCMV infection but show exacerbated HSC activation under systemic poly(I:C)-induced inflammation. We identify IFNβ as a primary target repressed by NFAT5, which opposes the master IFN-I inducer IRF3 by binding to an evolutionarily conserved sequence in the IFNB1 enhanceosome that overlaps a key IRF site. These findings illustrate how IFN-I responses are balanced by simultaneously opposing transcription factors.
Ruptured Chordae Tendineae
Authors: S W Miller, S A DeLuca
Journal: BMJ (1967)

s hypothesis, which is also Poskanzer's,' is that early exposure to infec- ton in low risk areas prevents the later development of M.S.If this were true, how- ever, the "unexposed" immigrants should show a much higher attack rate than is found in their native lands, which seems not to be the case in Australia, Dutch Antilles, Israel, or South Africa.Further, the native-born English-speaking South Africans, as well as the Israelis, are recent arrivals, and from neither land do the current prevalence studies indicate any appreciable rate of M.S. in the parents of the subjects.Thus the evidence suggests that M.S. is " caught" in the high risk areas and brought by the migrants in a latent form into these low risk regions which provide such an invaluable human laboratory for M.S.What is the latent period can perhaps be better defined from the points raised here with the data available to Dr.
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Authors: Greg J. Haro, Bonnie Sheu, Nancy R. Cook, Gavitt A. Woodard, Michael J. Mann, Johannes R. Kratz
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Improved staging for non–small cell lung cancer (NSCLC) represents a critical unmet need. External validations of the eighth edition of the TNM staging system have yielded disappointing results, with persistently high mortality observed in early-stage disease. <h3>Objective</h3> To determine whether incorporation of a molecular prognostic classifier into conventional TNM staging for NSCLC improves estimation of disease-free survival. <h3>Design, Setting, and Participants</h3> This cohort study was conducted at an academic, quaternary care medical center from 2012 to 2018. A consecutive series of 238 patients underwent surgical resection of stage I to IIIC nonsquamous NSCLC and had molecular prognostic classifier testing performed. Data analysis was conducted in May 2019. <h3>Exposures</h3> Patients were restaged according to the seventh and eighth editions of the TNM staging system and the novel TMMB staging system, which maintains the order and structure of the eighth edition of the TNM but downstages or upstages according to low or high molecular risk, respectively. <h3>Main Outcomes and Measures</h3> The primary outcome was disease-free survival 3 years from the time of surgical resection. Reclassification statistics were then used to evaluate performance and improvement measures of the TNM seventh and eighth editions and the TNMB staging system. <h3>Results</h3> Two hundred thirty-eight patients (144 [60.5%] female; median [interquartile range] age, 70 [63-75] years) were analyzed. The median (interquartile range) follow-up was 25 (14-40) months, and the disease-free survival rate was estimated to be 58.3% (95% CI, 45.7% to 69.0%). One hundred fifty-nine patients (66.8%) were reclassified by the TNMB staging system. Overall model fit remained the same for the seventh and eighth editions of the TNM staging system, whereas the<i>R</i><sup>2</sup>statistic (change from 0.22 to 0.31), concordance index (change from 0.68 to 0.73), and log-rank χ<sup>2</sup>(change from 38 to 108) were all associated with improvements after TNMB adoption. The TNMB system, compared with the TNM eighth edition, was associated with enhanced identification of high-risk patients and better differentiation of those without recurrence from those who had recurrence (net reclassification improvement, 0.28; 95% CI, 0.08 to 0.46;<i>P</i> &lt; .001), whereas the eighth edition compared with the seventh edition was not associated with improvement of this measure (net reclassification improvement, 0.02; 95% CI, –0.18 to 0.21;<i>P</i> = .87). <h3>Conclusions and Relevance</h3> The TNMB staging system was associated with improved estimation of disease-free survival compared with conventional TNM staging. Incorporation of a molecular prognostic classifier into staging for NSCLC may lead to better identification of high-risk patients.
DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Adi Diab, Miguel-Angel Perales, Adam Cohen, Vanessa M. Hubbard, Jeff Eng, Deonka Huggins, Manuel Engelhorn, Jose A. Guevarra, Onder Alpdogan, Jedd D. Wolchok, Adam Kochman, Alan N. Houghton, Marcel van den Brink
Journal: Blood (2004)
Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study
Authors: Rhonda E. Ries, Amanda R. Leonti, Timothy Junius Triche, Robert B. Gerbing, Betsy A Hirsch, Susana C. Raimondi, Jenny L. Smith, Todd M Cooper, Jason E. Farrar, Aniruddha J. Deshpande, E. Anders Kolb, Alan S Gamis, Richard Aplenc, Todd A. Alonzo, Soheil Meshinchi
Journal: Blood (2019)
BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia
Authors: Cihangir Duy, J. Jessica Yu, Leandro Cerchietti, Lars Klemm, Rahul Nahar, Yong-mi Kim, Nora Heisterkamp, Giovanni Martinelli, Wolf-Karsten Hofmann, Hassan Jumaa, Ari Melnick, B. Hilda Ye, Markus Muschen
Journal: Blood (2008)